Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

First-in-Human Safety Study for Fractomer™ Biomatrix

NCT: NCT07151638 · SUSPENDED

NCT IDNCT07151638
StatusSUSPENDED
Start Date2025-08-11
Completion2027-01-22
SponsorinSoma Bio, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to evaluate the safety of implanting a new medical device (Fractomer™ Biomatrix) in healthy volunteers. The main question it aims to answer is: How do healthy volunteers react to this injectable implant? Participants will receive a subcutaneous injection of Fractomer and their health will be monitored. After the monitoring period, the implant will be removed.

Frequently Asked Questions

What is First-in-Human Safety Study for Fractomer™ Biomatrix?

First-in-Human Safety Study for Fractomer™ Biomatrix is a clinical trial registered under NCT07151638. Current status: SUSPENDED.

What is the status of NCT07151638?

The current status of NCT07151638 (First-in-Human Safety Study for Fractomer™ Biomatrix) is: SUSPENDED.

When did First-in-Human Safety Study for Fractomer™ Biomatrix start?

First-in-Human Safety Study for Fractomer™ Biomatrix started on 2025-08-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.